These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23292838)

  • 1. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.
    Bozkurt S; Uz B; Buyukasik Y; Bektas O; Inanc A; Goker H; Kansu E
    Med Oncol; 2013 Mar; 30(1):443. PubMed ID: 23292838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
    Crisan AM; Coriu D; Arion C; Colita A; Jardan C
    J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
    Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Jabbour E; Kantarjian HM; Abruzzo LV; O'Brien S; Garcia-Manero G; Verstovsek S; Shan J; Rios MB; Cortes J
    Blood; 2007 Oct; 110(8):2991-5. PubMed ID: 17625066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.
    Landstrom AP; Knudson RA; Dewald GW; Ketterling RP; Tefferi A
    Leuk Lymphoma; 2007 Nov; 48(11):2137-40. PubMed ID: 17926177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.
    Feldman E; Najfeld V; Schuster M; Roboz G; Chadburn A; Silver RT
    Exp Hematol; 2003 Aug; 31(8):702-7. PubMed ID: 12901975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
    McNamara C; Grigg A; Szer J; Roberts A; Campbell L; Hoyt R; Lynch K; Juneja S
    Clin Lab Haematol; 2003 Apr; 25(2):119-25. PubMed ID: 12641616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
    Fabarius A; Haferlach C; Müller MC; Erben P; Lahaye T; Giehl M; Frank O; Seifarth W; Hehlmann R; Hochhaus A
    Haematologica; 2007 Jun; 92(6):834-7. PubMed ID: 17550857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.
    Luatti S; Castagnetti F; Marzocchi G; Baldazzi C; Gugliotta G; Iacobucci I; Specchia G; Zanatta L; Rege-Cambrin G; Mancini M; Abruzzese E; Zaccaria A; Grimoldi MG; Gozzetti A; Ameli G; Capucci MA; Palka G; Bernasconi P; Palandri F; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; Testoni N;
    Blood; 2012 Jul; 120(4):761-7. PubMed ID: 22692507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
    Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
    Fabarius A; Leitner A; Hochhaus A; Müller MC; Hanfstein B; Haferlach C; Göhring G; Schlegelberger B; Jotterand M; Reiter A; Jung-Munkwitz S; Proetel U; Schwaab J; Hofmann WK; Schubert J; Einsele H; Ho AD; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Lauseker M; Pfirrmann M; Hasford J; Saussele S; Hehlmann R;
    Blood; 2011 Dec; 118(26):6760-8. PubMed ID: 22039253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of Ph
    Ansari S; Verma M
    Med Oncol; 2023 Jul; 40(8):237. PubMed ID: 37439908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognosis of clonal chromosomal abnormalities in Philadelphia negative metaphases cells in chronic myeloid leukemia with tyrosine kinase inhibitor therapy].
    Zhao HF; Zhang Y; Hu JY; Li Z; Zhou J; Yu FK; Zu YL; Zhou H; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):209-214. PubMed ID: 30929388
    [No Abstract]   [Full Text] [Related]  

  • 18. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
    Terre C; Eclache V; Rousselot P; Imbert M; Charrin C; Gervais C; Mozziconacci MJ; Maarek O; Mossafa H; Auger N; Dastugue N; Talmant P; Van den Akker J; Leonard C; N'Guyen Khac F; Mugneret F; Viguié F; Lafage-Pochitaloff M; Bastie JN; Roux GL; Nicolini F; Maloisel F; Vey N; Laurent G; Recher C; Vigier M; Yacouben Y; Giraudier S; Vernant JP; Salles B; Roussi J; Castaigne S; Leymarie V; Flandrin G; Lessard M;
    Leukemia; 2004 Aug; 18(8):1340-6. PubMed ID: 15190256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
    Zaccaria A; Testoni N; Valenti AM; Luatti S; Tonelli M; Marzocchi G; Cipriani R; Baldazzi C; Giannini B; Stacchini M; Gamberini C; Castagnetti F; Rosti G; Azzena A; Cavazzini F; Cianciulli AM; Dalsass A; Donti E; Giugliano E; Gozzetti A; Grimoldi MG; Ronconi S; Santoro A; Spedicato F; Zanatta L; Baccarani M;
    Cancer Genet Cytogenet; 2010 Jun; 199(2):76-80. PubMed ID: 20471509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.